TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05498974

Intervention type: OTHER
Intervention: Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
Description: Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center

Intervention type: OTHER
Intervention: Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
Description: Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
Study: NCT04908761

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transmuscular quadratus lumborum block
Description: Patients assigned to the TQL block group receive the TQL block in a supine position with the surgical site facing up before recovery of general anesthesia after surgery. For the block, 30cc of 0.375% ropivacaine is used.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For patients assigned to the control group, 30cc of 0.9% normal saline is used for TQL block.
Study: NCT06267274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Ophthalmic Solution, 0.01%
Description: 1 drop of ophthalmic solution instill in both eyes every night at 10:00 pm (±1 hours) for 42 days (6 weeks) (± 4 days) as per the randomization schedule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
Description: 1 drop of ophthalmic solution instill in both eyes every night at 10:00 pm (±1 hours) for 42 days (6 weeks) (± 4 days) as per the randomization schedule.
Study: NCT05645913

Intervention type: DRUG
Intervention: Oral anticoagulant
Description: Oral anticoagulant that was continued at least 25days, inculding warfarin and new oral anticoagulant (NOAC)
Study: NCT04746716

Intervention type: OTHER
Intervention: Phone call
Description: Phone call to the patient to complete quality of life scales

Intervention type: OTHER
Intervention: Phone call
Description: Phone call to the patient to complete quality of life scales
Study: NCT04680780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-days water-fasting
Description: Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months. In one of the 3 months they are - if required - allowed to split the 3 days into periods of 1 and 2 days. On all other days of the intervention period they are allowed to eat ad libitum.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Patients are allowed to eat ad libitum, but will be advised that low salt intake (\< 5-7 g/day) and sufficient fluid intake (\>3 l/day) which is considered beneficial in ADPKD.
Study: NCT06432725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JUNTOS
Description: HIV test counselor and Latino MSM participants will be given access to the JUNTOS website/app, which shows information about local HIV and ancillary services. HIV test counselor participants will also be given access to a training video explaining how to use the JUNTOS website/app. HIV test counselors are encouraged to use the website/app for approximately 10 minutes at least once a week when meeting with Latino MSM testing clients. Latino MSM are encouraged to use the website/app to locate HIV and ancillary services as needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral Sheet
Description: HIV test counselor and Latino MSM participants will be given access to referral sheet, which is a list of local HIV and ancillary services. HIV test counselors are encouraged to use the referral sheet for approximately 10 minutes at least once a week when meeting with Latino MSM testing clients. Latino MSM are encouraged to use the referral sheet to locate HIV and ancillary services as needed.
Study: NCT06216028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Aspirate Concentrate
Description: Range of between 18.7 X 104 cells/mL and 21.8 X 106 cells/mL total nucleated cells (TNC)
Study: NCT04917393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iRF System Multi-organ Denervation
Description: If assigned to the treatment arm, subjects will remain blinded and recieve angiography prior to catheter based RF ablation to circumferentially disrupt the sympathetic nerves surrounding the target arteries

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Procedure
Description: If assigned to the control group, subjects will remain blinded and recieve angiography of the target arteries prior to sheath removal.
Study: NCT04862806

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 serology
Description: Immune response to BNT162b2 mRNA vaccine is assessed on the basis of anti covid19 IgG levels. A centralized assessment of the serological response for 4 medical centers is performed on serum samples stored at -60 °C using Abbott-SARS-CoV-2 IgG quant (Positive value \> 151; range 0-40.000). The other 4 medical centers performed the test locally using DiaSorins-LAISISON SARS-CoV S1/S2 IgG test (positive value \>15 range 15-400). In the central virus laboratory at the Chaim Sheba Medical center the test was done by Elisa-RDB (positive value \>1.1; range 1.1-10).
Study: NCT06256159

Intervention type: OTHER
Group type: OTHER
Intervention: 12 MSWS questionnaire
Description: The subject has to perform different gait assessments and fill out the 12-item multiple sclerosis walking scale questionnaire in one visit. Maximum 8 weekes after the first visit the subject has to fill out the same questionnaire again.
Study: NCT05991687

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-home drug disposal pouch
Description: Will receive a drug disposal pouch to inactivate leftover prescription opioids for disposal after surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mail-in prepaid envelope
Description: Will receive a prepaid envelope to mail leftover prescription opioids for disposal after surgery
Study: NCT04875585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy with Pembrolizumab/Lenvatinib
Description: Neoadjuvant therapy for 6 weeks
Study: NCT05318378

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: BIXAM
Description: Series two consisted of inverted and conventional X-rays of the same subject (BIXAM) shown together

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BIXAM
Description: Series two consisted of inverted and conventional X-rays of the same subject (BIXAM) shown together
Study: NCT06132399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: META QUEST 3 virtual reality glasses
Description: The RESET virtual reality software will be integrated into META QUEST 3 glasses (Meta Platforms, San Francisco, CA, US) by DYNAMICS.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan)
Description: This group will use the Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan) gaming system with the Sports package games.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The UC intervention consists of 3 sessions/week of 90' of physical therapy and occupational therapy conducted by a physiotherapist and an occupational therapist.
Study: NCT05751096

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity Focused Ultrasound (LIFU)
Description: repeat pulse application of low intensity focused ultrasound using a single element transducer to a selected neurological target for neuromodulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity Focused Ultrasound (LIFU)
Description: repeat pulse application of low intensity focused ultrasound using a single element transducer to a selected neurological target for neuromodulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low-intensity focused ultrasound (LIFU)
Description: Sham application of LIFU.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low-intensity focused ultrasound (LIFU)
Description: Sham application of LIFU.
Study: NCT05587218

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-production
Description: After participants learn L2 lexical items via hearing or observing them paired with L1 translations, they are prompted to produce them themselves

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-production
Description: After participants learn L2 lexical items via hearing or observing them paired with L1 translations, they are prompted to produce them themselves
Study: NCT04616027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 20 mg
Description: PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 20 mg
Description: PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 20 mg
Description: PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 20 mg
Description: PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 20 mg
Description: PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1
Study: NCT05045833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN-020 Delayed Release Capsule
Description: Oral administration (by mouth)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN-020 Delayed Release Capsule
Description: Oral administration (by mouth)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN-020 Delayed Release Capsule
Description: Oral administration (by mouth)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN-020 Delayed Release Capsule
Description: Oral administration (by mouth)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN-020 Delayed Release Capsule
Description: Oral administration (by mouth)
Study: NCT06184399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 1.5 mg ODT
Description: Oro-dispersible tablets of 1.5 mg ivermectin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 1.5 mg ODT
Description: Oro-dispersible tablets of 1.5 mg ivermectin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 1.5 mg ODT
Description: Oro-dispersible tablets of 1.5 mg ivermectin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 1.5 mg ODT
Description: Oro-dispersible tablets of 1.5 mg ivermectin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin 3 mg Oral Tablet
Description: Tablets of 3 mg ivermectin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole 400 mg Oral Tablet
Description: Tablets of 400 mg albendazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IVM ODT
Description: Placebo for ivermectin ODT
Study: NCT06448585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) treatment
Description: Treatment with subcutaneous polymerized 100 specific immunotherapy (SIT) in its initiation phase with rapid (clustered) dosing, where the highest allergen concentration (0.2 + 0.3 mL) is administered directly, with an interval of 30 to 45 minutes between injections, in allergology consultations of the SES.
Study: NCT06051760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NV-001
Description: NV-001 is a type of tumor vaccine generated by hybridization of the tumor cell membrane and adjuvant membrane to stimulate the immune reactions against cancer cells.
Study: NCT04609540

Intervention type: DRUG
Intervention: Trastuzumab
Description: Dual anti-HER2 therapy
Study: NCT06448585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) treatment
Description: Treatment with subcutaneous polymerized 100 specific immunotherapy (SIT) in its initiation phase with rapid (clustered) dosing, where the highest allergen concentration (0.2 + 0.3 mL) is administered directly, with an interval of 30 to 45 minutes between injections, in allergology consultations of the SES.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Specific immunotherapy (SIT) treatment
Description: Treatment with subcutaneous polymerized 100 specific immunotherapy (SIT) in its initiation phase with rapid (clustered) dosing, where the highest allergen concentration (0.2 + 0.3 mL) is administered directly, with an interval of 30 to 45 minutes between injections, in allergology consultations of the SES.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Specific immunotherapy (SIT) treatment
Description: Treatment with subcutaneous polymerized 100 specific immunotherapy (SIT) in its initiation phase with rapid (clustered) dosing, where the highest allergen concentration (0.2 + 0.3 mL) is administered directly, with an interval of 30 to 45 minutes between injections, in allergology consultations of the SES.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: ABB C1
Description: Ingredients: betaglucanos, levadura Saccharomyces cerevisiae, selenio y zinc.~1 sachet/day; contains 3 grams

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: ABB C1
Description: Ingredients: betaglucanos, levadura Saccharomyces cerevisiae, selenio y zinc.~1 sachet/day; contains 3 grams

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Supplement: ABB C1
Description: Ingredients: betaglucanos, levadura Saccharomyces cerevisiae, selenio y zinc.~1 sachet/day; contains 3 grams

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mini-tablets with pork extract
Description: Mini-tablets with pork extract containing the diamine oxidase enzyme (3 mini-tablets/day)
Study: NCT05976490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information and Support Intervention
Description: Information guide and four one-on-one coaching sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information and Support Intervention
Description: Information guide and four one-on-one coaching sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual supportive care
Description: Referral to cancer center supportive care services (e.g., social work) upon request from the patient, caregiver, or clinician
Study: NCT04875585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: surgical resection of primary tumor and lymph-node-dissection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Treatment Phase
Description: Adjuvant treatment with 15 cycles of Pembrolizumab
Study: NCT05078502

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: One capsule of vitamin D3(40000IU) weekly for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: One capsule of vitamin D3(40000IU) weekly for 8 weeks
Study: NCT06256198

Intervention type: OTHER
Intervention: measurement of serum lactate and procalcitonin and PCO2 gap
Description: measurement of serum lactate, procalcitonin and PCO2 gap

Intervention type: OTHER
Intervention: measurement of serum lactate and procalcitonin and PCO2 gap
Description: measurement of serum lactate, procalcitonin and PCO2 gap
Study: NCT05695534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR educational video
Description: Patients will be educated with our specifically made VR video in the settings of our hospital to make patients more familliar with the spaces and to explain them the procedure.
Study: NCT04884815

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UX701
Description: Nonreplicating, recombinant gene transfer vector

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UX701
Description: Nonreplicating, recombinant gene transfer vector

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UX701
Description: Nonreplicating, recombinant gene transfer vector

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UX701
Description: Nonreplicating, recombinant gene transfer vector

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UX701
Description: Nonreplicating, recombinant gene transfer vector

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline
Study: NCT06242470

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC026 Dose Escalation
Description: Escalating doses of MGC026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC026 Dose Escalation
Description: Escalating doses of MGC026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC026 Dose Escalation
Description: Escalating doses of MGC026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC026 Dose Escalation
Description: Escalating doses of MGC026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC026 Dose Escalation
Description: Escalating doses of MGC026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC026 Dose Escalation
Description: Escalating doses of MGC026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC026 Dose for Expansion
Description: MGC026 recommended dose for expansion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC026 Dose for Expansion
Description: MGC026 recommended dose for expansion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC026 Dose for Expansion
Description: MGC026 recommended dose for expansion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC026 Dose for Expansion
Description: MGC026 recommended dose for expansion
Study: NCT05266027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine Sebacate (Naldebain)
Description: Nalbuphine Sebacate (Naldebain) 2mL/150mg would be intramuscularly injected during knee arthroplasty surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo medication
Description: Placebo medication, Nalbuphine Sebacate not contained
Study: NCT04900623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NavDx HPV ctDNA Testing
Description: Blood will be collected and shared with an outside lab for analysis. This test will be done at Week 4 and at End of Treatment. This test will be done at at End of Treatment and in follow-up at 3, 6, 9, and 12 months after completing the study treatment. In years 2 and 3 after treatment, the test will be collected every 6 months or twice a year. The specimens will be identifiable. The specimens will be banked for future use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NavDx HPV ctDNA Testing
Description: Blood will be collected and shared with an outside lab for analysis. This test will be done at Week 4 and at End of Treatment. This test will be done at at End of Treatment and in follow-up at 3, 6, 9, and 12 months after completing the study treatment. In years 2 and 3 after treatment, the test will be collected every 6 months or twice a year. The specimens will be identifiable. The specimens will be banked for future use.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation Therapy (administered daily, Monday-Friday). Higher risk participants will receive standard radiation dose for up to 7-8 weeks. Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation Therapy (administered daily, Monday-Friday). Higher risk participants will receive standard radiation dose for up to 7-8 weeks. Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.
Study: NCT05062200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered as an oral tablet.
Study: NCT05727683

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
Description: Subjects will receive Lymphodepleting chemotherapy with intravenous (IV) fludarabine (25 mg/m2/day for 3 days) plus cyclophosphamide IV (250 mg/m2/day for 3 days) (flu/cy) concurrently, followed by JWCAR029 cells infusion. Phase 1 will evaluate up to 4 JWCAR029 cells dose levels.
Study: NCT06376019

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: solitary Implant loading with ball attachment
Description: ball attachment will be attached to the dental implant on the day of implant placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: splinted Implant loading with intra oral welding
Description: Titanium bar will be welded to the dental implant on the day of implant placement

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: complete denture
Description: Mucosa supported conventional complete denture will be fabricated without supporting implants
Study: NCT05346393

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS
Description: A transjugular intrahepatic portosystemic shunt (TIPS) is implanted into the cirrhotic liver

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Terlipressin/Albumin treatment is the preferred standard of care treatment. In the case Terlipressin is not tolerated treatment with Noradrenaline may be considered following actual guidelines.
Study: NCT05314504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YVOIRE Y-Solution 360
Description: Cross-linked sodium hyaluronate gel for injection with lidocaine
Study: NCT05621915

Intervention type: DRUG
Intervention: Nadroparin
Description: Subcutaneous injection of nadroparin according to the ICU guidelines for thromboprophylaxis in ICU patients.

Intervention type: DRUG
Intervention: Nadroparin
Description: Subcutaneous injection of nadroparin according to the ICU guidelines for thromboprophylaxis in ICU patients.

Intervention type: DRUG
Intervention: Nadroparin
Description: Subcutaneous injection of nadroparin according to the ICU guidelines for thromboprophylaxis in ICU patients.